Ambroxol

Phase 2Small molecule

Boehringer Ingelheim

Ambroxol is one of 176 small molecule programs targeting Peripheral Neuropathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

175

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral NeuropathyActive, not recruiting

Parkinson DiseaseActive, not recruiting

PneumoniaActive, not recruiting

Gaucher DiseaseActive, not recruiting

DementiaActive, not recruiting

Peripheral NeuropathyPreclinical

Active, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

Gaucher DiseasePhase 1/Phase 2

Active, not recruiting

DementiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Ambroxol

Boehringer Ingelheim

Phase 2

1 2

Primaxin

Pfizer

Preclinical

2 3

Innohep

Alnylam Pharmaceuticals

Preclinical

1 4

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 5

Zantac 150

CChattem

Preclinical

2 6

Retrovir

BBp Consulting, Inc

Preclinical

2 7

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 8

Mucinex

AAultman Health Foundation

Preclinical

1 9

Cancidas

FFresenius Kabi Oncology Ltd.

Preclinical

1 10

Tagamet

DDT MedTech, LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/AActive, not recruiting

Gaucher Disease

NCT07285369

Clinical

Trials by Indication[1]

Gaucher Disease3 trials

High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)

Active, not recruiting·AAgyany Pharma LTD·N/A·NCT07285369·12 enrolled

Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy

Completed·SShaare Zedek Medical Center·Phase 2·NCT03950050·40 enrolled

Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease

Suspended·EExsar Corporation·Phase 1/2·NCT01463215·20 enrolled

Clinical Trial2 trials

A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS

Unknown status·TThe Florey Institute of Neuroscience and Mental Health·Phase 2·NCT05959850·50 enrolled

Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

Unknown status·HHelse Fonna·Phase 2·NCT04588285·180 enrolled

Double-blind1 trial

Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00525044·249 enrolled

Interaction1 trial

A Drug-Drug Interaction Study of Ambroxol and Levodropropizine

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 1·NCT01573663·21 enrolled

Sore Throat1 trial

Ambroxol Spray Sore Throat Study

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01361802·494 enrolled

4 more indications

Pneumonia1 trial

A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia

Unknown status·BBeijing Grand Johamu Pharmaceutical Company, Ltd.··NCT05002192·10,000 enrolled

Peripheral Neuropathy1 trial

Effect of Ambroxol in Diabetic Peripheral Neuropathy

Unknown status·—·N/A·NCT05558878·80 enrolled

Dementia1 trial

Ambroxol as a Treatment for Parkinson's Disease Dementia

Unknown status·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT02914366·55 enrolled

Parkinson disease1 trial

Ambroxol in Disease Modification in Parkinson Disease

Completed·UUniversity College, London·Phase 2·NCT02941822·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Ambroxol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ambroxol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ambroxol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Boehringer Ingelheim

Ambroxol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Gaucher Disease3 trials

Clinical Trial2 trials

Double-blind1 trial

Interaction1 trial

Sore Throat1 trial

Pneumonia1 trial

Peripheral Neuropathy1 trial

Dementia1 trial

Parkinson disease1 trial

References

Drug Info

Quick Facts

Related News